Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2017 | Pages:
55 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Pipeline Review, H2 2017 Summary According to the recently published report 'Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Pipeline Review, H2 2017'; Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) pipeline Target constitutes close to 14 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Metabotropic glutamate receptor 2 is a protein encoded by the GRM2 gene. It is a receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. May mediate suppression of neurotransmission or may be involved in synaptogenesis or synaptic stabilization. The report 'Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Pipeline Review, H2 2017' outlays comprehensive information on the Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities. It also reviews key players involved in Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 3 and 9 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System and Cardiovascular which include indications Depression, Anxiety Disorders, Treatment Resistant Depression, Schizophrenia, Alzheimer's Disease, Chronic Pain, Cognitive Disorders, Epilepsy, Ischemia, Psychosis and Stroke. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - The report reviews Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics and enlists all their major and minor projects - The report assesses Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents
2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Overview 7 Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Therapeutics Development 8 Products under Development by Stage of Development 8 Products under Development by Therapy Area 9 Products under Development by Indication 10 Products under Development by Companies 11 Products under Development by Universities/Institutes 13 Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Therapeutics Assessment 15 Assessment by Mechanism of Action 15 Assessment by Route of Administration 17 Assessment by Molecule Type 18 Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Companies Involved in Therapeutics Development 19 Addex Therapeutics Ltd 19 Bristol-Myers Squibb Company 20 Denovo Biopharma LLC 20 Domain Therapeutics SA 21 Eli Lilly and Company 21 Johnson & Johnson 22 Merck & Co Inc 22 Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Drug Profiles 23 ADX-92639 - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 BMT-133218 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 DT-2442 - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 JNJ-40411813 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 JNJ-5515 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 LSN-2535717 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 LY-2607540 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 LY-2969822 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 LY-3020371 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 LY-341495 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 pomaglumetad methionil - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 Small Molecule to Modulate Metabotropic Glutamate Receptor 2 for Psychosis - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 Small Molecules to Antagonize mGlu2 for Anxiety and Depression - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 Small Molecules to Antagonize MGLUR2 for Cardiovascular and Central Nervous System Disorders - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Dormant Products 40 Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Discontinued Products 42 Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Product Development Milestones 43 Featured News & Press Releases 43 Feb 27, 2017: Addex's ADX71149 Anti-Epileptic Effect Highlighted in Scientific Journal, Epilepsia 43 Sep 23, 2015: Addex ADX71149 Demonstrates Synergistic Efficacy with Levetiracetam in Preclinical Models of Epilepsy 43 Feb 19, 2015: Addex mGluR2 NAM Demonstrates Protection in Preclinical Model of Ischemic Neuronal Death 44 Feb 07, 2014: Addex Reports Top-line Data from ADX71149 Phase 2a Study in Patients with Major Depressive Disorder with Significant Anxiety Symptoms 44 Oct 29, 2013: Addex Licensee Completes Enrolment of 120 Patients in a Phase 2 Clinical Trial of ADX71149 for the Treatment of Anxious Depression 45 Nov 05, 2012: Addex Reports Top-line Data From Successful Phase IIa Clinical Study With ADX71149 In Schizophrenia Patients 46 Nov 05, 2012: Addex Therapeutics Reports Top-line Data From Phase IIa Clinical Study With ADX71149 In Schizophrenia Patients 47 Sep 17, 2012: Addex Partner Doses First Patient In Phase II Clinical Study Of ADX71149 For Treatment Of Major Depressive Disorder Patients With Anxiety Symptoms 48 Aug 29, 2012: Lilly Stops Phase III Development Of Pomaglumetad Methionil For Treatment Of Schizophrenia Based On Efficacy Results 49 Jul 11, 2012: Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint Of Clinical Study 49 Jun 05, 2012: Janssen To Initiate Phase II Clinical Trial Of ADX71149 For Treatment Of Major Depressive Disorder With Anxiety Symptoms 50 Mar 28, 2011: Addex Partner Starts Phase IIa Clinical Trial Of ADX71149 In Schizophrenia 50 Sep 02, 2010: Addex's mGluR2 Shows Efficacy In Alzheimer's Disease Model 52 Aug 25, 2010: Addex Partner Completes ADX71149 Phase I Program 52 Jun 24, 2009: Addex Partner Starts First-Ever Clinical Trial Of An mGluR Positive Allosteric Modulator 53 Appendix 54 Methodology 54 Coverage 54 Secondary Research 54 Primary Research 54 Expert Panel Validation 54 Contact Us 54 Disclaimer 55
List of Tables
Number of Products under Development by Stage of Development, H2 2017 8 Number of Products under Development by Therapy Areas, H2 2017 9 Number of Products under Development by Indication, H2 2017 10 Number of Products under Development by Companies, H2 2017 11 Products under Development by Companies, H2 2017 12 Number of Products under Investigation by Universities/Institutes, H2 2017 13 Products under Investigation by Universities/Institutes, H2 2017 14 Number of Products by Stage and Mechanism of Actions, H2 2017 16 Number of Products by Stage and Route of Administration, H2 2017 17 Number of Products by Stage and Molecule Type, H2 2017 18 Pipeline by Addex Therapeutics Ltd, H2 2017 19 Pipeline by Bristol-Myers Squibb Company, H2 2017 20 Pipeline by Denovo Biopharma LLC, H2 2017 20 Pipeline by Domain Therapeutics SA, H2 2017 21 Pipeline by Eli Lilly and Company, H2 2017 21 Pipeline by Johnson & Johnson, H2 2017 22 Pipeline by Merck & Co Inc, H2 2017 22 Dormant Products, H2 2017 40 Dormant Products, H2 2017 (Contd..1), H2 2017 41 Discontinued Products, H2 2017 42
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
